非布司他治疗痛风伴高尿酸血症的应用效果评定被引量：6

下载PDF

导出

摘要目的探讨非布司他治疗痛风伴高尿酸血症的应用效果。方法以2014年4月-2016年1月我院痛风伴高尿酸血症患者75例作为对象,将其随机分为别嘌呤醇组和非布司他组。别嘌呤醇组给予别嘌呤醇治疗;非布司他组给予非布司他治疗。比较两组患者痛风伴高尿酸血症治疗总有效率;治疗前后血尿酸水平;治疗初期痛风急性发作率。结果非布司他组患者痛风伴高尿酸血症治疗总有效率显著比别嘌呤醇组高(P<0.05);两组患者治疗前血尿酸水平差异无统计学意义(P>0.05);非布司他组治疗后血尿酸水平显著比别嘌呤醇组好(P<0.05);非布司他组患者治疗初期痛风急性发作率明显低于别嘌呤醇组(P<0.05)。结论非布司他治疗痛风伴高尿酸血症的应用效果确切,可有效改善血尿酸水平,控制痛风发作,值得推广。

作者张丽梅王丽

机构地区云南省曲靖市第一人民医院风湿免疫科

出处《实用妇科内分泌电子杂志》 2016年第9期132-132,134,共2页 Electronic Journal of Practical Gynecological Endocrinology

关键词非布司他痛风伴高尿酸血症应用效果

分类号 R589.7 [医药卫生—内分泌]

引文网络
相关文献

参考文献3

1蒋兰兰,金星,沈赟,马建华,吴锦丹.非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J].实用医学杂志,2014,30(17):2827-2830. 被引量：97
2谷丽梅.非布司他治疗痛风伴高尿酸血症疗效观察[J].中国卫生标准管理,2016,7(7):106-107. 被引量：18
3谭源源.非布司他治疗痛风伴高尿酸血症的有效性及安全性分析[J].中国现代医药杂志,2015,17(9):61-62. 被引量：13

二级参考文献23

1Terkeltauh R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [J]. Arthritis Res Ther, 2006, 8( Suppl 1) : S4.
2Chao 1, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout [J]. CUff Rheumatol Rep, 2009,11 (2): 135-140.
3Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout [J]. Cochrane Database Syst Rev, 2012, 14 (1):11.
4Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase ill , randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008,59(11):1540-1548.
5Schumacher HR, Becker MA, Lioyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study [J]. Rheumatology(Oxford), 2009,48(2): 188-194.
6El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? [J]. Cleve Clin J Med, 2010,77(12):919-928.
7Ernst ME, Fravel MA. Febuxostat , a selective xanthine-oxidase/ xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout [J]. Clin Ther, 2009, 31 ( 11 ) : 2503-2518.
8Ye P, Yang SM, Zhang WL, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis [J]. Clin Ther, 2013 , 35 (2): 180-189.
9Becker MA, Schumacher HR Jr , Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [J]. Arthritis Rheum, 2008,58(suppI9) :L11.
10Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for international Clinical Studies Including Therapeutics (ESCISIT) [J]. Ann Rheum Dis, 2006, 65( 10): 1312-1324.